Holen Sie sich die Stockscreener-App
13.12
2.26%
0.29
Schlusskurs vom Vortag:
$12.83
Offen:
$12.83
24-Stunden-Volumen:
1.06M
Relative Volume:
0.42
Marktkapitalisierung:
$4.19B
Einnahmen:
$3.02B
Nettoeinkommen (Verlust:
$127.93M
KGV:
59.29
EPS:
0.2213
Netto-Cashflow:
$225.64M
1W Leistung:
+6.49%
1M Leistung:
+10.90%
6M Leistung:
+34.98%
1J Leistung:
+81.97%
1-Tages-Spanne:
$12.82
$13.22
1-Wochen-Bereich:
$12.30
$13.22
52-Wochen-Spanne:
$7.01
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.12 | 4.00B | 3.02B | 127.93M | 225.64M | 0.2213 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Is AMRX stock undervalued? Sales multiple, target, upside - MSN
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. - Yahoo! Finance Canada
Amneal launches generic bimatoprost 0.01% to US market - Eyes On Eyecare
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced the official launch of Albuterol Sulfate and Beclomethasone Dipropionate HFA inhalation aerosols in the U.S. market. - Bitget
Institution Moves: Is Amneal Pharmaceuticals Inc a strong candidate for buy and hold2026 Price Momentum & Low Risk High Reward Ideas - baoquankhu1.vn
Aug Fed Impact: Is Amneal Pharmaceuticals Inc in a long term uptrend2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Should Amneal’s New Generic Glaucoma Launch Shape How AMRX Investors View Its Specialty Strategy? - Sahm
Fund Flows: Is Amneal Pharmaceuticals Inc forming a double bottomEarnings Overview Summary & Fast Momentum Entry Tips - baoquankhu1.vn
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook - qz.com
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing - qz.com
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside - qz.com
Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN
AMRX: 3 Key Factors Fueling Amneal's Projections for 2026 - Bitget
Here's the way AMRX is leveraging the demand for GLP-1 via its manufacturing operations - Bitget
Why Amneal Pharmaceuticals (AMRX) Stands Out as a Leading Long-Term Growth Stock - Bitget
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
FOCUS-Patients scramble to find estrogen patches as shortage worsens after US FDA champions use - Sahm
Is It Time To Reassess Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Share Price Run? - Sahm
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Launching Its New Glaucoma Generic - Yahoo Finance
FDA sends latest Untitled Letters to Amneal, BioCorRx over brochures, websites - Medical Marketing and Media
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% - Bitget
AMRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volatility Watch: Whats the fair value of Amneal Pharmaceuticals Inc stock2026 Historical Comparison & Proven Capital Preservation Tips - baoquankhu1.vn
Amneal marks Parkinson's Awareness Month, $2M donation - Post Register
Amneal to Report First Quarter 2026 Results on May 1, 2026 - The Manila Times
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month - The Manila Times
$2M from Amneal targets Parkinson's drug costs for patients - Stock Titan
Trading Recap: Whats the fair value of Amneal Pharmaceuticals Inc stockRate Cut & Low Volatility Stock Recommendations - baoquankhu1.vn
Allspring Global Investments Holdings LLC Grows Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Pharma News: Is Amneal Pharmaceuticals Inc in a long term uptrend2026 Geopolitical Influence & Technical Pattern Recognition Alerts - baoquankhu1.vn
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Amneal Pharmaceuticals Stock: Generic Drug Leader Faces Recall Challenges Amid Sector Growth Opportu - AD HOC NEWS
Tudor Investment Corp ET AL Takes Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
JPMorgan Chase & Co. Has $7.72 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by SG Americas Securities LLC - MarketBeat
Amneal Pharmaceuticals (AMRX) price target increased by 13.79% to 16.83 - msn.com
AMRX SEC FilingsAmneal Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Amneal (NYSE: AMRX) Co-CEO receives major performance-based RSU award - Stock Titan
[Form 4/A] Amneal Pharmaceuticals, Inc. Amended Insider Trading Activity - Stock Titan
Suboxone Market Size Forecasts 2026-2033: Analyzing Industry - openPR.com
Major holder Dipan Patel cuts Amneal Pharmaceuticals (AMRX) stake to 5.4% - Stock Titan
Vanguard (AMRX) disaggregates holdings, reports 0 Amneal shares after realignment - Stock Titan
Amneal Pharmaceuticals (NASDAQ: AMRX) posts 2025 growth and seeks backing for board slate - Stock Titan
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Amneal Pharmaceuticals stock gains momentum as Truist raises target to $17 amid analyst optimism - AD HOC NEWS
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):